PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

NCT06549855 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer
Endometrioid Carcinoma
Mismatch Repair Deficiency

Interventions

DRUG: Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]